How can I enhance my orphan drug development?
Accelerating orphan drug development from candidate selection to commercial manufacture and supply
With over 300 million people worldwide living with identified rare diseases, the development of new treatments to address these unmet clinical needs is an area of great interest in the pharmaceutical industry.
Despite improvements in regulatory support and commercial rewards for developing orphan drugs, difficulties remain for drug developers in bringing these medicines to market quickly; including limited R&D budgets, alongside an ever-evolving regulatory framework, challenging product development and clinical recruitment.
Integrated capabilities and expertise
At Quotient Sciences we have supported over 50 development programs for rare disease in the past 5 years. Our extensive formulation know-how, clinical pharmacology expertise, coupled with our agile and flexible approach to clinical and commercial manufacturing, makes us the ideal partner.
From pre-formulation and formulation development through clinical development and scale up for commercial manufacturing we provide an end-to-end solution for the development of orphan drug products. Our extensive expertise and capabilities for orphan drug development includes:
- Pre-formulation and API characterisation.
- Formulation and process development.
- First-in-human clinical testing and acceleration into POC trials.
- Bespoke clinical manufacturing and supply (Phase I-III) of drug products into patient trials.
- Rapid scale-up and commercial manufacturing of low-volume products.
As a fully integrated drug development, clinical testing and manufacturing organization, Quotient Sciences addresses the challenges associated with developing programs for rare diseases and orphan drug development . We are dedicated to accelerating the development of new drugs for patients around the world providing individual services or fully integrated programs through our unique Translational Pharmaceutics platform.
Connect with us today to learn how we can help support the development and manufacturing needs of your orphan drug program.
Related content
Learn more about orphan drug development
-
WhitepaperAccelerating the Developing of Orphan Drugs for Rare DiseasesWorldwide there are over 300 million people living with identified rare diseases. This white paper will discuss four principal CMC challenges for the developers of orphan drugs, and the potential solutions which are emerging.
-
ArticleDevelopment of a Once‑Daily Modified‑Release Formulation for the Short Half‑Life RIPK1 Inhibitor GSK2982772 using DiffCORE TechnologyQuotient Sciences Scientific Publication- Development of a Once‑Daily Modified‑Release Formulation for the Short Half‑Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
-
Info SheetHuman ADME CapabilitiesWith over 30 years’ experience as a world leading provider of human ADME 14C radiolabeled studies, we have the scientific expertise and operational know-how to design and deliver human ADME programs in preparation for NDA, MAA and global regulatory filings.
-
Scientific PostersAn integrated radiolabelled study to determine the mass balance, metabolite profile and identification, and absolute bioavailability of nolasiban in healthy female subjectsQuotient Sciences Poster : An Integrated Radiolabelled Study to Determine the Mass Balance, Metabolite Profile and Identification and Absolute Bioavailability of Nolasiban in Healthy Female Subjects
Ready to get started?
Share your project needs with us.
We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.